EUVIMEDEUVIMED entdecken
Crossref

Determining plasma and cerebrospinal fluid concentrations of EGFR-TKI in lung cancer patients

Guan-Yuan Chen, Sheng-Kai Liang, Yu-Feng Wei, Te-I Weng, Kuan-Yu Chen

Analytical Biochemistry · 2023-05 · 669 · 115115

DOI: 10.1016/j.ab.2023.115115 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Analytical Biochemistry, 2023-05. Verfasst von Guan-Yuan Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Forensic and Clinical Toxicology Center, National Taiwan University Hospital, Taipei, Taiwan; Department and Graduate Institute of Forensic Medicine,…. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Ministry of Science and Technology, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are commonly used to treat advanced non-small cell lung cancer (NSCLC). A rapid and reliable method for measuring plasma and cerebrospinal fluid (CSF) concentrations of EGFR-TKIs is needed for therapeutic drug monitoring. By using UHPLC‒MS/MS with multiple reaction monitoring mode, we developed a method for rapidly determining the plasma and CSF concentrations of gefitinib, erlotinib, afatinib, and osimertinib. Protein precipitation was employed to remove protein interference for plasma and CSF matrix. The LC‒MS/MS assay was validated to be satisfactory in terms of linearity, precision, and accuracy. This method was successfully applied to measure plasma (n = 44) and CSF (n = 6) concentrations of EGFR-TKIs in NSCLC patients. The chromatographic separation was achieved by a Hypersil Gold aQ column within 3 min. The median plasma concentrations were 325.76, 1981.50, 42.62, 40.27, and 340.92 ng/ml for gefitinib erlotinib, afatinib 30 mg/day, afatinib 40 mg/day, and osimertinib, respectively. The CSF penetration rates were 2.15% for the patients receiving erlotinib therapy, 0.59% for afatinib, 0.08-1.12% for osimertinib 80 mg/day, and 2.18% for those receiving osimertinib 160 mg/day. This assay helps to predict the effectiveness and toxicities of EGFR-TKIs in the pursuit of precision medicine for lung cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungHumansAfatinibErlotinib HydrochlorideGefitinibTandem Mass SpectrometryChromatography, LiquidProtein Kinase InhibitorsErbB ReceptorsMutationAcrylamidesAniline CompoundsIndolesPyrimidines

Stichwörter der Autor:innen

EGFR-TKILC‒MS/MSLung cancerPrecision medicineTherapeutic drug monitoring

Substanzen

AfatinibErlotinib HydrochlorideGefitinibProtein Kinase InhibitorsErbB ReceptorsosimertinibAcrylamidesAniline CompoundsIndolesPyrimidines

Autor:innen und Institutionen

  • Forensic and Clinical Toxicology Center, National Taiwan University Hospital, Taipei, Taiwan; Department and Graduate Institute of Forensic Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Department of Internal Medicine, National Taiwan University Hospital Hsinchu Branch, Hsinchu, Taiwan; Department of Medicine, National Taiwan University Cancer Center, Taipei, Taiwan.
  • School of Medicine for International Students, College of Medicine, and Institute of Biotechnology and Chemical Engineering, I-Shou University, Kaohsiung, Taiwan; Department of Internal Medicine, E-Da Cancer Hospital, K…
  • Forensic and Clinical Toxicology Center, National Taiwan University Hospital, Taipei, Taiwan; Department and Graduate Institute of Forensic Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan; Depa…
  • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address: tuff.chen@m…

Förderung

  • Ministry of Science and Technology, Taiwan

Zitieren

APA

Chen, G. Y., Liang, S. K., Wei, Y. F., Weng, T. I., & Chen, K. Y. (2023). Determining plasma and cerebrospinal fluid concentrations of EGFR-TKI in lung cancer patients. Analytical Biochemistry, 669, 115115. https://doi.org/10.1016/j.ab.2023.115115

Vancouver

Chen GY, Liang SK, Wei YF, Weng TI, Chen KY. Determining plasma and cerebrospinal fluid concentrations of EGFR-TKI in lung cancer patients. Analytical Biochemistry. 2023;669:115115. doi:10.1016/j.ab.2023.115115

BibTeX
@article{Chen2023,
  author = {Chen, Guan-Yuan and Liang, Sheng-Kai and Wei, Yu-Feng and Weng, Te-I and Chen, Kuan-Yu},
  title = {Determining plasma and cerebrospinal fluid concentrations of EGFR-TKI in lung cancer patients},
  journal = {Analytical Biochemistry},
  year = {2023},
  volume = {669},
  pages = {115115},
  doi = {10.1016/j.ab.2023.115115}
}
Kostenlos starten →